Evaluate The Effect Of Consecutive Intravitreal Avastin Injections On Macular Edema In Patients With Retinal Vein Occlusion(RVO)

Purpose: To evaluate the effect of intravitreal Avastin (Bevacizumab; Genentech, Inc.) injections on visual acuity and foveal retinal thickness in patients with retinal vein occlusion(RVO).Methods:In this prospective noncomparative consecutive inter venetional case series,40 patients received 3 consecutive intravitreal injection of bevacizumab (2.5mg/ 0.1ml) at 1 month intervals.Best-corrected visual acuity testing (Snellen charts),intraocular pressure measurement and retinal thickness measurement were performed before therapy and follow-up examinations.Results: There were 40 patients who received intravitreal avastin injections.The follow-up was 6 months.The mean visual acuity (logMAR) improved from 1.088±0.681 at baseline to 0.47±0.44 at 6 months (p < 0.001 the differences was statistically significant).The mean central 1 mm macular thickness was 623.83±195.67μm at baseline and decreased to 275.30±103.96μm at 6 month ( p < 0.001 the differences was statistically significant). No adverse side effects were observed following injections.Conclusion: Intravitreal injection of bevacizumab resulted in a significant decrease in macular edema and improvement in visual acuity. No adverse events were observed.